Karolinska Institutet

What Karolinska Institutet does

Karolinska Institutet (KI) is Sweden's largest medical university and accounts for the single largest share of all academic medical research conducted in Sweden. Founded in 1810, KI is a public government university headquartered in Solna with additional campuses in Flemingsberg, co-located with Karolinska University Hospital. It educates medical and health sciences students at undergraduate, graduate, and doctoral levels, conducts biomedical research across the full medical spectrum, and hosts the Nobel Assembly responsible for awarding the Nobel Prize in Physiology or Medicine. KI's core technological platforms include multi-omics research infrastructure, the Karolinska ATMP Center for cell and gene therapy development, the KI Biobank (500,000+ donor samples), the Genomic Medicine Center, and the newly inaugurated Centre for AI Innovation.

KI operates an array of specialized research centers that translate discovery into clinical and commercial outcomes: the Karolinska ATMP Center (one of Europe's leading cell and gene therapy hubs), the Precision Medicine Center Karolinska, the Centre for Health Crises (medical preparedness, disaster, and defence medicine), and the Centre for AI Innovation. Notable research outputs include a gene therapy restoring sight in 11 of 12 hereditary blindness patients, the Stockholm3 blood test achieving 90% prostate cancer detection versus 74% for standard PSA, AI-driven antibiotic discovery against drug-resistant gonorrhoea published in Science Translational Medicine, and 82.5% successful desensitization in preschool peanut allergy trials.

KI's business model is that of a public-sector research university rather than a commercial enterprise. Revenue is derived from Swedish government appropriations, competitive research grants (European Research Council, EU Horizon, Wallenberg Foundation, Swedish Research Council), philanthropic donations, and tuition from non-EU/EEA students. Education for EU/EEA students is government-subsidized. The institution owns a wholly-owned investment subsidiary, Karolinska Development, which manages a portfolio of life science companies. Recent major capital inflows include a SEK 1.6 billion Wallenberg Foundation allocation, SEK 80 million from the Gysell family for prostate cancer research, EUR 5 million in ERC Advanced Grants, USD 9 million from the Leducq Foundation, and SEK 123 million in Swedish government funding for precision medicine and medical preparedness.

Name

Karolinska Institutet

Legal name

Karolinska Institutet

Website

https://ki.se

Company type

Private

Founded year

1810

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Karolinska Institutet is Sweden's largest medical university, conducting the single largest share of the country's academic medical research, hosting the Nobel Assembly, and educating medical students across campuses in Solna and Flemingsberg.

Ownership category

akta.pro rank

Product category

Medical Research and Health Sciences Education

NAICS

Colleges, Universities, and Professional Schools (6113), Colleges, Universities, and Professional Schools (611310), Professional, Scientific, and Technical Services (541)

SIC

Services-Educational Services (8200), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Medical Laboratories (8071)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Global Health Institutes & Programs (EDAHAGAM)

Keywords

• Medical research
• Medical education
• Biomedical sciences
• Precision medicine
• Translational research

Headquarters

HQ city

Solna

HQ country

Sweden

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Government funding: Primary revenue from Swedish government appropriations for higher education and research, representing the largest share of academic medical research funding in Sweden
2. Research grants: Competitive research funding from Swedish Research Council, European Research Council (ERC), European Union Horizon programs, Wallenberg Foundations, and other international funding bodies
3. Philanthropic donations: Private donations for specific research initiatives, such as SEK 80 million from Björn Gysell family for prostate cancer research and SEK 30 million for advanced prostate cancer therapies
4. Government precision medicine investment: Swedish government SEK 63 million investment supporting Precision Medicine Center Karolinska and regional centers for advanced diagnostics integration

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Karolinska Institutet is Sweden's largest medical university, offering the largest portfolio of medical and health sciences degree programs in the country and conducting the single largest share of academic medical research in Sweden. Its offerings span undergraduate and doctoral education, biomedical and clinical research across all medical disciplines, advanced therapy medicinal products (ATMP), precision medicine, and AI-driven medical innovation.

Product overview

Karolinska Institutet is Sweden's largest medical university offering a portfolio of research centers and initiatives rather than commercial products. Key offerings include the Karolinska ATMP Center for cell and gene therapy development, the Centre for AI Innovation for medical AI research, the Precision Medicine Center Karolinska for personalized healthcare, and the KI Research Incubator (KIRI) for researcher innovation support. The institution also conducts extensive clinical research through partnerships with healthcare providers.

Differentiator

Problem solved

Functional benefit

Brands

• Centre for AI Innovation: A center inaugurated in 2025 to accelerate development and adoption of trustworthy AI in medical research and healthcare through collaboration, health data access, testing environments, and strategic alliances
• Precision Medicine Center Karolinska
• Centre for Health Crises
• Karolinska ATMP Center
• Centre of Excellence for Sustainable Health

Products and services

• Medical and Health Sciences Degree Programs Largest portfolio of medical and health sciences degree programs in Sweden, including undergraduate medicine, dentistry, nursing, biomedicine, allied health professions, master's and doctoral programs, with EU/EEA students receiving government-subsidized tuition.
• Karolinska ATMP Center Center facilitating collaboration between healthcare, universities, and pharmaceutical companies for the development, manufacturing, and delivery of cell and gene therapies (Advanced Therapy Medicinal Products).
• Centre for AI Innovation Center bringing together researchers, clinicians, policymakers, and industry partners to accelerate the development and adoption of trustworthy AI in medical research and healthcare through collaboration, health data access, testing environments, and strategic alliances.
• Precision Medicine Center Karolinska Center focused on developing long-term, equitable integration of advanced diagnostics and personalized treatment into healthcare, including precision diagnostics and personalized therapy across Sweden.
• Centre for Health Crises Multidisciplinary platform consolidating KI's activities in medical preparedness, covering health crises, disaster medicine, and defence-related medicine.
• Centre of Excellence for Sustainable Health Collaboration between Karolinska Institutet and Makerere University in Uganda focused on sustainable health systems, producing 64 PhD graduates, over 500 peer-reviewed publications, and more than 400 student and lecturer exchanges.
• Executive Programme in International Politics and Diplomacy for Health Executive education program jointly hosted with Stockholm School of Economics that brings together emerging health leaders from government, civil society, academia, and the private sector to build diplomatic skills for global health.
• KI Biobank Biological sample repository storing samples from over 500,000 donors, including the Biobank of Karolinska Endarterectomies, supporting large-scale multi-omics and clinical research programs.

Quantifiable outcome

• 90% detection rate for aggressive prostate cancer vs 74% for standard PSA test using Stockholm3 blood test
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability2 records

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Stockholm School of EconomicscoreStrategic or Co-development Partner · 25 June 2026Joint Executive Programme in International Politics and Diplomacy for Health masterclass in Sigtuna, Sweden, bringing together 33 emerging health leaders from government, civil society, academia, and private sector to build diplomatic skills for global health
• FORTIFY (34-partner public-private initiative)coreStrategic or Co-development Partner · 2 June 202634-partner initiative funded by Innovative Health Initiative aligned with European Health Data Space, developing legal guidance, governance tools, and technical solutions for IP-sensitive secondary use of health data across Europe (May 2026 - April 2029)
• Institute of Applied Biosciences (INAB) at CERTH, GreececoreStrategic or Co-development Partner · 12 May 2026Formal partnership agreement strengthening academic cooperation in research, education, and innovation, building on 20+ years of collaboration focused on cancer research and hematological malignancies including joint projects, staff exchange, and educational programs
• TikoMed ABminorStrategic or Co-development Partner · 25 February 2026Letter of intent signed for ILBIAMI clinical study evaluating ILB effect in limiting heart muscle damage following myocardial infarction; KI serves as study sponsor while TikoMed provides active product and scientific support
• NeurotechEU University AlliancecoreStrategic or Co-development Partner · 12 February 2026Europe-wide doctoral network connecting researchers in neurotechnology, offering online activities, on-site meetings, workshops, courses, and peer exchange; KI serves as application recipient for the network
• Novo NordiskcoreStrategic or Co-development Partner · 10 February 2026Strategic partnership since 2019 for multi-omics research on unstable atherosclerosis; collaboration includes EU Horizon NextGen project for improved patient stratification and novel therapeutic targets
• Makerere University, UgandacoreStrategic or Co-development Partner · 25 October 202525-year collaboration producing 64 PhD graduates, over 500 peer-reviewed publications, and more than 400 student and lecturer exchanges; partnership delivers practical health improvements from midwifery training to stroke rehabilitation
• St. Erik Eye HospitalcoreStrategic or Co-development Partner · 4 September 2025Expanded collaboration on Advanced Therapy Medicinal Products (ATMP) to accelerate transition of cell- and gene-based therapies from research to clinical application, focusing on retinal diseases; anchored at Karolinska ATMP Center
• MITcoreStrategic or Co-development PartnerInternational collaboration on AI-driven antibiotic discovery where KI researchers contributed proteomics-based methods to identify compound mechanism of action against gonorrhoea bacteria
• KTH Royal Institute of TechnologycoreStrategic or Co-development PartnerJoint research with KTH to create insulin-producing cells from human stem cells for Type 1 diabetes treatment; lab-grown cells successfully responded to glucose and restored blood sugar control in diabetic mice
• Columbia UniversityminorStrategic or Co-development PartnerCollaborative study on organ transplantation rates among celiac disease patients finding three-fold higher transplantation rates compared to general population
• Swedish emergency preparedness systemcoreStrategic or Co-development PartnerSEK 60 million investment for new thematic platform consolidating KI activities in medical preparedness including health crises, disaster medicine, and defence-related medicine; aims to position KI as knowledge hub

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Imperial College London Faculty of Medicine: Major UK medical school with comparable translational research model integrated with NHS hospitals; competes for EU/UK research grants and international student pipeline.
• Harvard Medical School: Global benchmark for academic medical research with affiliated teaching hospitals; comparable in MD-granting, biomedical research output, and Nobel-affiliated faculty, with a substantially larger endowment.
• University of Oxford Medical Sciences Division: Top European competitor medical school with comparable MD programs, biomedical research output, and industry partnerships; competes for ERC funding and global recruitment of early-career researchers.
• ETH Zurich: European technical/STEM research powerhouse; a peer through its life sciences and bioengineering departments, and as a competing institution for international research talent and EU framework funding.

Direct peers

• Karolinska University Hospital: Affiliated teaching hospital co-located with KI; both share faculty, conduct joint clinical research, and operate as an integrated academic medical center — the closest operational peer given direct translational coupling.
• Lund University Faculty of Medicine: Sweden's second major medical faculty and recipient of Wallenberg Centre for Molecular Medicine funding; directly competes with KI for Swedish government research appropriations, ERC grants, and clinical research talent.
• Uppsala University Faculty of Medicine: One of Sweden's oldest and largest medical faculties; competes with KI for Swedish research funding, graduate students, and Nobel Assembly representation.
• Gothenburg University Sahlgrenska Academy: Sweden's third major medical faculty; directly competes for ALF-medel government funding, medical students, and clinical research partnerships with Sahlgrenska University Hospital.
• KTH Royal Institute of Technology: KI's joint research partner on insulin-producing stem cells for Type 1 diabetes; fellow Swedish public research institution and close collaborator with overlapping life science capabilities and faculty.
• Karolinska Development: Wholly-owned investment subsidiary of KI that manages and develops life science portfolio companies emerging from KI research; closely linked commercial translation arm that monetizes KI discoveries.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights8 records

Customer concentration

• Facebookfacebook.com/karolinskainstitutet
• LinkedInlinkedin.com/company/karolinska-institutet
• Instagraminstagram.com/kibiblioteket
• Xx.com/karolinskainst

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karolinska Institutet